Furthermore, we discuss the compromise of this pathway in Alzheimer’s disease (AD), explaining the well-established atrophy of NGF-dependent cholinergic neurons of the basal forebrain (BF), and the possibility of deriving accessible biomarkers of AD in preclinical stages based on the NGF metabolic deregulation. The gene discussed is NGF; the disease is Alzheimer disease.